MedTrace Logo

R(+)PPX High Dose Treatment of ALS

NCT00600873 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2010-09-13

No results posted yet for this study

Summary

R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.

Conditions

Interventions

DRUG

R(+) pramipexole dihydrochloride monohydrate

100 mg tid orally daily

Sponsors & Collaborators

  • Bennett, James P., Jr., M.D., Ph.D.

    lead INDIV

Principal Investigators

  • Ted M Burns, MD · University of Virginia

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-09-30
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600873 on ClinicalTrials.gov